Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma

Chan Ho Lee1, Soo Jin Jung2, Won Ik Seo1, Jae Il Chung1, Dae Sim Lee3, Dae Hoon Jeong3, Youkyoung Jeon4 and Inhak Choi4

Abstract

Objectives: Lymphocyte-activation gene 3 (LAG-3) represents a potential immune checkpoint target for cancer treatment. We investigated LAG-3 expression and its prognostic value in patients with surgically treated clear cell renal cell carcinoma (RCC) and correlated LAG-3 expression with programmed cell death ligand 1 (PD-L1).

Methods: We evaluated LAG-3 and PD-L1 expression using immunohistochemistry on tissue microarrays incorporating 134 primary excision specimens of clear cell RCC (ccRCC). The patients were analyzed as two groups: the whole cohort and those with metastatic RCC (mRCC). The cancer genome atlas (TCGA) data analysis of LAG-3 was done through UALCAN web servers.

Results: Using the UALCAN cancer transcriptional data analysis, we found that LAG-3 was overexpressed in ccRCC. LAG-3 expression was significantly correlated with PD-L1 expression in the whole cohort and in the mRCC group (all, p < 0.05). Both LAG-3⁺ RCC and PD-L1⁺ RCC presented with a higher TNM stage and higher Fuhrman nuclear grade (all, p < 0.05). PD-L1⁺/LAG-3⁺ RCC and PD-L1⁺/LAG-3⁻ RCC showed poorer cancer-specific survival (CSS) than PD-L1⁻/LAG-3⁻ RCC (all, p = 0.01). Similarly, PD-L1⁺/LAG-3⁻ mRCC and PD-L1⁺/LAG-3⁻ mRCC showed poorer CSS than PD-L1⁻/LAG-3⁻ mRCC (all, p < 0.05). Multivariate analysis showed that PD-L1⁺/LAG-3⁺ RCC (hazard ratio: 3.19; 95% CI: 0.77–13.67; p = 0.033) was a predictor of poor CSS.

Conclusion: Both LAG-3⁺ and PD-L1⁺ RCC have adverse pathological features, and their coexpression predicts worse clinical outcomes. Our findings suggest LAG-3 blockade in combination with programmed cell death 1/PD-L1 blockade as a potential therapeutic approach for RCC.

Keywords
lymphocyte-activation gene 3, renal cell carcinoma, immunotherapy, immune checkpoints, tumor microenvironment

Date received: 6 April 2022; accepted: 24 August 2022

1Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
2Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
3Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
4Department of Microbiology and Immunology, Innovative Therapeutics Research Institute, Inje University College of Medicine, Busan, Korea

Corresponding author:
Soo Jin Jung, Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, 75Bokji-ro, Busanjin-gu, Busan 47392, Republic of Korea.
Email: soojinmd@hanmail.net

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Renal cell carcinoma (RCC) comprises approximately 90% of kidney cancer cases, of which 70% are clear cell RCC (ccRCC). Although the surgical resection of early-stage RCC has a good prognosis, the 5-year survival rates for relapsed or metastatic RCC (mRCC) have traditionally been quite low (0%–20%). In systemic treatment for mRCC, systemic cytokine therapy, followed by targeted therapies, including tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR), have been reported to prolong survival. However, approximately 20%–25% of patients derive no benefit from first-line targeted therapy or become treatment-resistant. Fortunately, the introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment paradigm for mRCC. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4, programmed cell death 1 (PD-1) receptor, or PD-1 ligand (PD-L1) have shown clinical efficacy in mRCC treatment. Despite improved survival and treatment efficacy using ICIs, the treatment efficacy of the checkpoint blockade in mRCC remains limited to a specific subpopulation of patients. Thus, efforts are being made to find alternative pathways and auxiliary targets to overcome the limited efficacy of ICI treatment and treatment resistance.

Lymphocyte-activation gene 3 (LAG-3), also known as CD233, is an example of a new immune checkpoint target. This inhibitory receptor is mainly found on activated immune cells (ICs) and is involved in negative regulatory effects on T-cells and their biological functions related to immune and inflammatory responses. Based on the coexpression of LAG-3 with other inhibitory receptors, recent preclinical and clinical evidence has revealed PD-1 pathway blockade in combination with LAG-3 inhibition as a potentially effective immunotherapy strategy. However, the expression of LAG-3 and its coexpression with PD-L1 in primary RCC tissue has not been fully investigated. Additionally, the prognostic role of LAG-3 expression in RCC and the synergistic effect on prognosis upon coexpression with PD-L1 remains unclear. Therefore, we investigated the clinicopathological and prognostic significance of the coexpression of LAG-3 and PD-L1 in primary ccRCC tumors. In addition, the association of LAG-3 mRNA expression with immune cells was analyzed using The Cancer Genome Atlas (TCGA) ccRCC database.

Methods

Patients

This study was retrospective in nature. The inclusion criteria for patient enrollment are as follows: We obtained samples from 134 patients diagnosed with ccRCC by clinical, radiological, and histopathological assessment. All patients underwent radical or partial nephrectomy at Inje University Busan Paik Hospital, South Korea, between January 2011 and January 2019. They had no other history of other malignancies and did not undergo radiotherapy or chemotherapy before surgical treatment. The exclusion criteria were (1) subjects with rheumatic immune disease, (2) other types of tumors, and (3) incomplete information. All pathological tissue specimens were provided by Inje Biobank. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a prior approval by the Institutional Review Board of Inje University Busan Paik Hospital (approval no. 20–0121). Data on the histopathological features, such as histological subtype, tumor size, lymphovascular invasion, sarcomatoid features, Fuhrman nuclear grade, and distant metastases at surgery, were collected. The pathological stage was determined according to the 2010 version of the American Joint Committee on Cancer TNM staging system and the Heidelberg classification of renal tumors. The follow-up duration was calculated from the date of surgery to the date of the last follow-up or death. The study patients were analyzed as two groups, namely, the whole cohort and those with mRCC (determined according to the metastatic disease and systemic treatment status during follow-up). Clinical information regarding demographic characteristics, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, and follow-up data were extracted from the patients’ electronic medical records.

Confirmation of LAG-3 expression and association with immune cells in clear cell RCC

UALCAN (http://ualcan.path.uab.edu/), an interactive website for analyzing cancer transcriptome data (TCGA - KIRC), was used to determine the effects of PD-L1 and LAG-3 in ccRCC patients. We used cancer transcriptome data to evaluate stage-dependent changes in expression and survival of both genes in ccRCC patients and data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) to assess the effect on PD-L1 expression in protein expression analysis. Timer analysis was used to investigate the correlation between infiltration of various immune cells and prognosis of the ccRCC patients according to the status of expression of LAG-3 within the tumor.

Tissue microarrays (TMAs) and immunohistochemistry

Six TMA blocks comprising a total of 402 cores with 2-mm diameter were constructed using custom-made precision
instrument (Beecher Instruments, Silver Spring, MD). Triplicate from 3 different regions including invasive margin and tumor center containing viable and representative tumor cells (TCs) and stroma with tumor-infiltrating ICs after review of whole tissue section slide in each formalin-fixed paraffin-embedded (FFPE) primary RCC tissue blocks of 134 patients was made. LAG-3 and PD-L1 expression were analyzed in 4-μm-thickness serial sections from each TMA block by immunohistochemistry (IHC). Normal human FFPE tonsil sections treated with and without these primary antibodies were used as positive and negative controls, respectively. Antigen retrieval was performed at 120°C for 10 min in citrate buffer, pH 6.0, using a pressure cooker. IHC staining was performed on a BenchMark ULTRA automated platform (Ventana), according to the manufacturer’s protocol. The following primary antibodies were used and incubated for 2 h at room temperature: anti-LAG-3 mAb (1:200; clone D2G4O, Cell Signaling Technology, MA, USA), PD-L1 (1:100; clone SP263, Ventana Medical Systems, Inc., AZ, USA). After conjugation with an antibody-bound enzyme, the detection was carried out using a Dako REAL EnVision Detection System (LAG3, K5007; Agilent Technologies, CA, USA) and OptiView DAB IHC Detection Kit (PDL1, Ventana Medical Systems, Tucson, AZ).

**Figure 1.** Expression of LAG-3 and PD-L1 in ccRCC patients using UALCAN. mRNA levels of LAG-3, (a) and PD-L1, (d) in ccRCC tissues and adjacent normal renal tissues. LAG-3 (b) and PD-L1, (e) mRNA expression in normal tissues and ccRCC tissues according to tumor stage. Kaplan-Meier survival curves of patients with ccRCC according to LAG-3, (c) or PD-L1, (f) mRNA expression. PD-L1 protein expression in ccRCC tissues and normal renal tissues (g), and PD-L1 protein expression in normal tissues and ccRCC tissues differing in tumor stage, (h) Data are mean ± SE ***p < 0.001, **p < 0.01, *p < 0.05 from respective expression of normal tissue. TPM: Transcript per million.

**LAG-3 and PD-L1 scoring**

Tissue microarrays and individual slides were visually scored by an experienced pathologist blinded to clinical information. LAG-3 and PD-L1 scoring of ICs is a controversial matter in the current literature; in our study, we used the method of Burugu et al. and Motzer et al. LAG-3 scores were reported as absolute counts, and any positive expression on ICs (≥1 IC per TMA core) was used for dichotomization into positive and negative cases. IC expression of PD-L1 was assessed as the percentage of ICs with membranous or cytoplasmic expression; any cores with ≥1% of PD-L1+ ICs were considered positive. All IC types, including macrophages and lymphocytes, were counted together to calculate the LAG-3 and PD-L1 scores. PD-L1 expression in TCs was assessed as the percentage of carcinoma cells with membranous expression at any intensity. Any expression of ≥1% in a TMA core that included at least 100 evaluable TCs was considered positive. For the final statistical analysis, PD-L1+ cells were defined as any positive PD-L1 staining on ICs or TCs. The three tumor TMA cores for each case were independently scored, and if any of the three cores were positive, that case was considered positive in the statistical analysis.
Statistical analysis

Continuous variables were presented as means (standard deviation) or medians (interquartile ranges, IQRs). Categorical variables were presented as frequencies with percentages. Differences in the distribution of variables among groups were evaluated using the chi-square test, Fisher exact test, and linear-by-linear association for categorical variables. The Student t-test was used for continuous variables. Cancer specific survival according to the expression status of immune markers was estimated using the Kaplan–Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional-hazard models adjusted by LAG-3 and PD-L1 expression status were utilized to identify any clinicopathological factors that might have affected CSS. The risk was expressed as the hazard ratio (HR), and the 95% confidence interval (CI) was determined using the reference groups. Statistical analysis was performed with SPSS v25.0 (IBM Corp., Armonk, NY, USA) and MedCalc v20.0 (MedCalc Software, Ostend, Belgium). In all tests, a two-sided p-value < 0.05 was considered statistically significant.

Results

LAG-3 and PD-L1 expression in TCGA data

The cancer genome atlas data were analyzed using UALCAN to predict the effect of the mRNA expression of LAG-3 and PD-L1 on the cancer progression of ccRCC patients. The mRNA expression of LAG-3 was significantly increased in cancer tissues of ccRCC compared to normal tissues (Figure 1(a)), and the expression was increased according to the stage of cancer patients (Figure 1(b)). The survival rate of high LAG-3 mRNA expression group was lower than that of the medium/low LAG-3 mRNA expression group (p = 0.049). This indicates that higher degree of the expression of LAG-3 in ccRCC patients could potentially cause poorer prognosis (Figure 1(c)). The mRNA expression of PD-L1 was also increased in cancer tissues of ccRCC compared to normal tissues (Figure 1(d)). The patients with high PD-L1 mRNA expression showed better survival rate than patients with medium and low PD-L1 mRNA expression (Figure 1(f)). However, unlike the analysis using PD-L1 mRNA expression, the protein expression of PD-L1 in ccRCC was increased in the tissues of cancer by stage compared to normal tissues (Figure 1(e) and (h)).

Patient characteristics

The study cohort comprised 134 patients who underwent surgical resection of primary ccRCC. The patients' demographic data and clinicopathological features are summarized in Table 1. The median age of the whole cohort at the time of surgery was 61 years (IQR, 34–82), and the 134 patients included 94 men (70.1%). Among the 134 cases, 25 (18.7%) presented with synchronous metastasis, and 26 (19.4%) experienced disease recurrence during the follow-up period. Of the 51 patients with metastatic disease, 45 were treated with targeted therapy, including TKIs and mTOR inhibitors. Six patients were excluded as they refused systemic treatments. According to the IMDC risk classification, 20 (44.4%) of these patients were classed as favorable risk, 10 (22.2%) as intermediate risk, and 15 (33.3%) as poor risk. During a mean follow-up period of 89.6 months (95% CI: 80.0–99.3 months; median survival, not reached), 32 of the 134 (23.9%) patients died after surgery for ccRCC. In the case of mRCC, 28 patients (62.2%) died after diagnosis of metastatic disease, with a median follow-up of 18.0 months (95% CI: 11.0–43.0).

LAG-3 and PD-L1 expression

Immunohistochemistry detected the expression of LAG-3 protein in the nucleus and cytoplasm of ICs, but LAG-3
protein was not detected on TCs. In the whole cohort of 134 ccRCC patients, LAG-3 was positive in 68 (50.7%) cases. The expression of PD-L1 on ICs was positive in 45 (33.6%) cases, whereas 34 (25.4%) expressed PD-L1 on TCs. Taken together, PD-L1⁺ RCC was observed in 59 (44.0%) ccRCC patients. LAG-3 was positive in 31 (68.9%) mRCC patients. PD-L1⁺ ICs and TCs were observed in 20 (44.4%) and 17 (37.8%) mRCC patients, of which 25 (55.6%) were PD-L1⁺ mRCC. LAG-3 expression was significantly correlated with PD-L1 expression in the whole cohort and with mRCC. In summary, in the whole cohort, 64.7% of the cases with LAG-3⁺ RCC were PD-L1⁺, whereas 77.3% of the cases with LAG-3⁺ RCC were PD-L1⁻ (p < 0.001). Similarly, in mRCC, 67.7% of the cases with LAG-3⁺ mRCC were PD-L1⁺, whereas 71.4% of the cases with LAG-3⁺ mRCC were PD-L1⁻ (p = 0.016) (Table 2) (Figure 2).

### Table 1. Clinicopathologic characteristics for renal cell carcinoma patients.

| Characteristic                        | Whole cohort | Metastatic RCC |
|---------------------------------------|--------------|----------------|
|                                       | N = 134      | N = 45         |
| Age at surgery, years (median, IQR)   | 61 (34–82)   | 63 (40–81)     |
| Gender, n (%)                         |              |                |
| Male                                  | 94 (70.1)    | 32 (71.1)      |
| Female                                | 40 (29.9)    | 13 (28.9)      |
| Tumor size, cm (median, IQR)          | 5.5 (1.2–13) | 6.5 (1.2–9.2)  |
| T stage, n (%)                        |              |                |
| pT1                                   | 78 (58.2)    | 12 (26.7)      |
| pT2                                   | 19 (14.2)    | 9 (20.0)       |
| pT3                                   | 33 (24.6)    | 21 (46.7)      |
| pT4                                   | 4 (3.0)      | 3 (6.7)        |
| N stage, n (%)                        |              |                |
| cN0                                   | 122 (91.0)   | 35 (77.8)      |
| cN1                                   | 12 (9.0)     | 10 (22.2)      |
| M stage, n (%)                        |              |                |
| cM0                                   | 109 (81.3)   | 22 (48.9)      |
| cM1                                   | 25 (18.7)    | 23 (51.2)      |
| Stage, n (%)                          |              |                |
| Stage I                               | 72 (53.7)    | 6 (13.3)       |
| Stage II                              | 15 (11.2)    | 5 (11.1)       |
| Stage III                             | 22 (16.4)    | 11 (24.4)      |
| Stage IV                              | 25 (18.7)    | 23 (51.1)      |
| Fuhrman nuclear grade, n (%)          |              |                |
| G1–G2                                 | 65 (48.5)    | 10 (22.2)      |
| G3                                    | 51 (38.1)    | 20 (44.4)      |
| G4                                    | 18 (13.4)    | 15 (33.3)      |
| Lymphovascular invasion, n (%)        |              |                |
| No                                    | 118 (88.1)   | 34 (75.6)      |
| Yes                                   | 16 (11.9)    | 11 (24.4)      |
| Sarcomatoid features, n (%)           |              |                |
| No                                    | 126 (94.0)   | 39 (86.7)      |
| Yes                                   | 8 (6.0)      | 6 (13.3)       |
| Tumor necrosis, n (%)                 |              |                |
| No                                    | 103 (76.9)   | 24 (53.3)      |
| Yes                                   | 31 (23.1)    | 21 (46.7)      |
| IMDC risk classification              |              |                |
| Favorable                             | -            | 20 (44.4)      |
| Intermediate                          | -            | 10 (22.2)      |
| Poor                                  | -            | 15 (33.3)      |
Clinicopathological significance of LAG-3 and PD-L1 expression

Both LAG-3⁺ RCC and PD-L1⁺ RCC presented with higher TNM stage and higher Fuhrman nuclear grade (all, \( p < 0.05 \)) (Figure 3). PD-L1⁺ RCC presented with more tumor necrosis (\( p = 0.028 \)) (Table 3). Both LAG-3⁺ mRCC and PD-L1⁺ mRCC presented with more IMDC intermediate and poor risk patients than LAG-3⁻ mRCC and PD-L1⁻ mRCC (all, \( p < 0.05 \)). Only PD-L1⁺ mRCC showed higher TNM stage, higher Fuhrman nuclear grade, more sarcomatoid features, and more tumor necrosis (all, \( p < 0.05 \)).

Relationship of cancer specific survival with LAG-3 and PD-L1 expressions

Patients with LAG-3⁺ RCC had significantly poorer CSS than patients with LAG-3⁻ RCC. The mean CSS was 60.4 months (95% CI: 50.9–69.9) in LAG-3⁺ RCC and 101.4 months (95% CI: 89.1–113.6) in LAG-3⁻ RCC (HR: 3.11; 95% CI: 1.53–6.30; \( p = 0.0016 \)) (Figure 4(a)). Similarly, patients with PD-L1⁺ RCC showed significantly poorer CSS than patients with PD-L1⁻ RCC (mean, 63.7 months [95% CI: 53.6–73.7] vs. mean, 96.3 months [95% CI: 84.8–107.8]; HR: 2.31; 95% CI: 1.11–4.77; \( p = 0.0236 \)) (Figure 4(b)). The differences between the four subgroups classified according to LAG-3 and PD-L1 expression were not statistically significant, but PD-L1⁺/LAG-3⁺ RCC showed poorer CSS than PD-L1⁻/LAG-3⁻ RCC (mean, 62.7 months [95% CI: 50.9–74.5] vs. mean, 105.4 months [95% CI: 92.5–118.4]; HR: 4.62; 95% CI: 1.80–11.87; \( p = 0.0014 \)). Additionally, PD-L1⁺/LAG-3⁻ RCC showed poorer CSS than PD-L1⁻/LAG-3⁻ RCC (mean, 60.5 months [95% CI: 46.7–74.3] vs. mean, 105.4 months [95% CI: 92.5–118.4]; HR: 6.26; 95% CI: 1.93–20.26; \( p = 0.0022 \)) (Figure 4(c)).

Similar results were also observed in mRCC. The median CSS was 13.0 months (95% CI: 6.0–36.0) in LAG-3⁺ mRCC and 43.0 months (95% CI: 9.0–43.0) in LAG-3⁻ mRCC (HR: 2.30; 95% CI: 1.05–5.06; \( p = 0.0369 \)) (Figure 4(d)). The median CSS was 22.5 months (95% CI: 13.0–31.9) in PD-L1⁺ mRCC and 11.0 months (95% CI: 5.0–45.0) in PD-L1⁻ mRCC (HR: 2.09; 95% CI: 0.95–4.59; \( p = 0.0639 \)) (Figure 4(e)). PD-L1⁺/LAG-3⁺ mRCC showed poorer CSS than PD-L1⁻/LAG-3⁻ mRCC (median, 11.0 months [95% CI: 5.00–45.0] vs. not reached; HR: 2.91; 95% CI: 1.05–8.04; \( p = 0.0389 \)). PD-L1⁻/LAG-3⁻ mRCC also showed poorer CSS than PD-L1⁺/LAG-3⁻ mRCC (median, 30.0 months [95% CI: 4.00–37.0] vs. not reached; HR: 4.74; 95% CI: 1.35–16.61; \( p = 0.0149 \)) (Figure 4(f)).

In the univariate analysis, LAG-3⁺, PD-L1⁺, and PD-L1⁺/LAG-3⁺ (all, \( p < 0.05 \)) were significant unfavorable prognostic factors in the whole cohort and in the mRCC group (Table 4 and Supplemental Table 1). Multivariate analysis revealed only PD-L1⁺/LAG-3⁺ mRCC (HR: 3.19; 95% CI: 0.77–13.67; \( p = 0.033 \)) as a predictor of poor CSS (Table 4).

Discussion

Recently, several immune checkpoints on tumor-infiltrating ICs, which are key regulators of the immune escape of cancer cells, were studied and clinically applied to the treatment of various solid tumors. In primary ccRCC, PD-1, or PD-L1 inhibitors, which are hallmark immunological treatments, have offered a survival benefit in this decade. However, even after such immunotherapy, a significant number of patients still show refractory disease or acquire resistance. Therefore, demands for new therapeutic targets have emerged, of which is LAG-3 is attracting attention.

LAG-3 is mainly expressed in activated in activated CD4⁺ and CD8⁺ T cells, TCR-Natural Killer T Cells (NKT), and Regulatory T cells (Treg). Furthermore, coexpression of LAG-3 and PD-1 has been reported under pathological

Table 2. Expression of LAG-3 and PD-L1 in clear cell renal cell carcinoma.

| Characteristics | LAG-3 in whole cohort | LAG-3 in metastatic RCC |
|-----------------|-----------------------|------------------------|
|                 | Total | Positive | Negative | \( p \) value | Total | Positive | Negative | \( p \) value |
| PD-L1 in ICs, n (%) |       |         |         |           |       |         |         |           |
| Positive | 45 (33.6) | 34 (50.0) | 11 (16.7) | <0.001 | 20 (44.4) | 16 (51.6) | 4 (28.6) | 0.154 |
| Negative | 89 (66.4) | 34 (50.0) | 55 (83.3) |         | 25 (55.6) | 15 (48.4) | 10 (71.4) |         |
| PD-L1 in TCs, n (%) |       |         |         |           |       |         |         |           |
| Positive | 34 (25.4) | 25 (36.8) | 9 (13.6) | 0.002 | 17 (37.8) | 15 (48.4) | 2 (14.3) | 0.030 |
| Negative | 100 (74.6) | 43 (63.2) | 57 (86.4) |         | 28 (62.2) | 16 (51.6) | 12 (85.7) |         |
| PD-L1 in overall, n (%) |       |         |         |           |       |         |         |           |
| Positive | 59 (44.0) | 44 (64.7) | 15 (22.7) | <0.001 | 25 (55.6) | 21 (67.7) | 4 (28.6) | 0.016 |
| Negative | 75 (56.0) | 24 (35.3) | 51 (77.3) |         | 20 (44.4) | 10 (32.3) | 10 (71.4) |         |
conditions in inflammatory or tumor microenvironment. Based on these studies, we performed TCGA data analysis and tissue staining to determine whether the expression of LAG-3 and PD-L1, the counter partner of PD-1, indicates a poorer prognosis in ccRCC.

Our study clearly showed that the expression of LAG-3 in ccRCC was restricted to immune cells. Similarly, Panda et al. have reported that expression of the cytotoxic T-cell marker CD8A is strongly correlated with LAG-3 expression in various cancers, including RCC. However, it is necessary to confirm the correlation with other cells and analyze the reason for the decrease in the survival rate despite the correlation with CD8. Therefore, we analyzed the expression of LAG-3 and its effect on immune cells through TCGA data analysis using Timer analysis to evaluate the intracellular expression of LAG-3 and its effect on the cancer microenvironment (Supplemental Figure 1). As a result, it was confirmed that as the cancer cells’ purity

Figure 2. Expression of LAG-3 and PD-L1 by immunohistochemistry on serial section of same tissue. (a) LAG-3 and PD-L1 in immune cells (ICs), (b) LAG-3 in ICs and PD-L1 in tumor cells (TCs). Original magnification, ×200.

Figure 3. Expression of LAG-3 by immunohistochemistry according to Fuhrman nuclear grade of clear cell renal cell carcinoma. Fuhrman grade 2 (a), grade 3 (b), grade 4 (c), sarcomatous differentiation (d). Original magnification, ×200.
increased, the cancer cells had a negative correlation with the expression of LAG-3. Also, along with the our IHC results, in immune cells, except for CD4 resting memory T cells and Myeloid derived suppressor cells (MDSCs), the expression of LAG-3 and the degree of invasion of cancer tissues showed a positive correlation. In addition, as a result of analyzing the survival rate using the degree of invasion of various immune cells and the expression of LAG-3, an increase in the infiltration of CD4 activated memory T cells, NKT, and MDSCs caused a decrease in the survival rate. These results suggest that LAG-3 expressed in immune cells may be involved in regulating the invasion or the

| Table 3. Relationship of LAG-3 expression and clinicopathologic features in clear cell renal cell carcinoma. |
|--------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic     | Whole cohort     | Metastatic RCC  |                |                |                |                |                |
|                    | LAG-3 negative  | LAG-3 positive  | p value        | PD-L1 negative | PD-L1 positive | p value        | PD-L1 negative | PD-L1 positive | p value |
| Pathologic T stage |                 |                |                |                |                |                |                |                |        |
| pT1                | 47 (71.2)        | 31 (45.6)       | 0.006          | 50 (66.7)       | 28 (47.5)       | 0.008          | 5 (35.7)        | 7 (22.6)       | 0.210   |
| pT2                | 7 (10.6)         | 12 (17.6)       | 11 (14.7)      | 8 (13.6)        | 4 (28.6)        | 5 (16.1)       | 5 (25.0)        | 4 (16.0)       |        |
| pT3                | 10 (15.2)        | 23 (33.8)       | 13 (17.3)      | 20 (33.9)       | 4 (28.6)        | 17 (54.8)      | 6 (30.0)        | 15 (60.0)      |        |
| pT4                | 2 (3.0)          | 2 (2.9)         | 1 (1.3)        | 3 (5.1)         | 1 (7.1)         | 2 (6.5)        | 0 (0.0)         | 3 (12.0)       | 0.002   |
| Clinical N stage,  |                 |                |                |                |                |                |                |                |        |
| n (%)              |                |                |                |                |                |                |                |                |        |
| cN0                | 62 (93.9)        | 60 (88.2)       | 0.249          | 72 (96.0)       | 50 (84.7)       | 0.024          | 12 (85.7)       | 23 (74.2)      | 0.394   |
| cN1                | 4 (6.1)          | 8 (11.8)        | 3 (4.0)        | 9 (15.3)        | 2 (14.3)        | 8 (25.8)       | 1 (5.0)         | 9 (36.0)       | 0.014   |
| Clinical M stage,  |                 |                |                |                |                |                |                |                |        |
| n (%)              |                |                |                |                |                |                |                |                |        |
| cM0                | 59 (89.4)        | 50 (73.5)       | 0.018          | 68 (90.7)       | 41 (69.5)       | 0.002          | 9 (64.3)        | 13 (41.9)      | 0.169   |
| cM1                | 7 (10.6)         | 18 (26.5)       | 7 (9.3)        | 18 (30.5)       | 5 (35.7)        | 18 (58.1)      | 5 (25.0)        | 18 (72.0)      | 0.002   |
| Stage, n (%)       |                 |                |                |                |                |                |                |                |        |
| Stage I            | 45 (68.2)        | 27 (39.7)       | 0.001          | 46 (61.3)       | 26 (44.1)       | 0.003          | 3 (21.4)        | 3 (9.7)        | 0.076   |
| Stage II           | 6 (9.1)          | 9 (13.2)        | 11 (14.7)      | 4 (6.8)         | 3 (21.4)        | 2 (6.5)        | 5 (25.0)        | 0 (0.0)        |        |
| Stage III          | 8 (12.1)         | 14 (20.6)       | 11 (14.7)      | 11 (18.6)       | 3 (21.4)        | 8 (25.8)       | 5 (25.0)        | 6 (24.0)       |        |
| Stage IV           | 7 (10.6)         | 18 (26.5)       | 7 (9.3)        | 18 (30.5)       | 5 (35.7)        | 18 (58.1)      | 5 (25.0)        | 18 (72.0)      |        |
| Fuhrman nuclear grade, n (%) |      |                |                |                |                |                |                |                |        |
| G1–G2              | 40 (60.6)        | 25 (36.8)       | 0.004          | 46 (61.3)       | 19 (32.2)       | <0.001         | 4 (28.6)        | 6 (19.4)       | 0.264   |
| G3                 | 21 (31.8)        | 30 (44.1)       | 24 (32.0)      | 27 (45.8)       | 7 (50.0)        | 13 (41.9)      | 10 (50.0)       | 10 (40.0)      |        |
| G4                 | 5 (7.6)          | 13 (19.1)       | 5 (6.7)        | 13 (22.0)       | 3 (21.4)        | 12 (38.7)      | 2 (10.0)        | 13 (52.0)      |        |
| Lymphovascular invasion, n (%) |      |                |                |                |                |                |                |                |        |
| No                 | 61 (92.4)        | 57 (83.8)       | 0.125          | 68 (90.7)       | 50 (84.7)       | 0.296          | 12 (85.7)       | 22 (71.0)      | 0.292   |
| Yes                | 5 (7.6)          | 11 (16.2)       | 7 (9.3)        | 9 (15.3)        | 2 (14.3)        | 9 (29.0)       | 3 (15.0)        | 8 (32.0)       | 0.192   |
| Sarcomatoid features, n (%) |      |                |                |                |                |                |                |                |        |
| No                 | 63 (95.5)        | 63 (92.5)       | 0.495          | 73 (97.3)       | 53 (89.8)       | 0.069          | 12 (85.7)       | 27 (87.1)      | 0.900   |
| Yes                | 3 (4.5)          | 5 (7.4)         | 2 (2.7)        | 6 (10.2)        | 2 (14.3)        | 4 (12.9)       | 0 (0.0)         | 6 (24.0)       | 0.020   |
| Tumor necrosis, n (%) |      |                |                |                |                |                |                |                |        |
| No                 | 55 (83.3)        | 48 (70.6)       | 0.081          | 63 (84.0)       | 40 (67.8)       | 0.028          | 8 (57.1)        | 16 (51.6)      | 0.733   |
| Yes                | 11 (16.7)        | 20 (29.4)       | 12 (16.0)      | 19 (32.2)       | 6 (42.9)        | 15 (48.4)      | 6 (30.0)        | 15 (60.0)      | 0.048   |
| IMDC risk group    |                 |                |                |                |                |                |                |                |        |
| Favorable          | -                | -               | -              | -               | -               | -              | 10 (71.4)       | 10 (32.3)      | 0.045   |
| Intermediate       | -                | -               | -              | -               | -               | -              | 1 (7.1)         | 9 (29.0)       | 4 (20.0) |
| Poor               | -                | -               | -              | -               | -               | -              | 3 (21.4)        | 12 (38.7)      | 2 (10.0) |

International Journal of Immunopathology and Pharmacology
Figure 4. Kaplan–Meier curves of cancer specific survival (CSS) in the whole cohort and metastatic renal cell carcinoma according to expression of lymphocyte-activation gen 3 (LAG-3) and programmed cell death ligand-1 (PD-L1). Cancer specific survival in patients with LAG-3+ (a) and PD-L1+ (b) were significantly lower than with LAG-3- and PD-L1- (p = 0.0016, p = 0.0236). PD-L1+/LAG-3+ group was showed significantly lower CSS than PD-L1-/LAG-3-, PD-L1-/LAG-3+ and PD-L1+/LAG-3- groups (p = 0.0014, p = 0.0022, p = 0.0474) (c) in whole cohort. In metastatic RCC group, LAG-3+ patients were significantly lower than LAG-3- patients (p=0.0369) (d) and PD-L1+ patients were showed lower CSS than PD-L1- (p = 0.0639) (e). PD-L1+/LAG-3+ mRCC group was showed significantly lower CSS than PD-L1-/LAG-3-, PD-L1-/LAG-3+ and PD-L1+/LAG-3- mRCC groups (p = 0.0389, p = 0.0149, p = 0.0401) (f).

function of these three types of cells to regulate the cancer microenvironment.

Similarly, tumor-infiltrating lymphocytes isolated from patients with hepatocellular carcinoma, ovarian cancer, breast cancer, and melanoma showed significant upregulation of LAG-3. Additionally, these studies noted the function of LAG-3 as an immune checkpoint molecule, demonstrating its potential role as a target for cancer immunotherapy in various solid tumors. However, only a limited number of studies examining the role of LAG-3 in kidney
cancer using tissues derived from kidney cancer patients have been reported. Giraldo et al.\textsuperscript{22} reported the prognostic role of PD-L2 and LAG-3 in the immunomodulation of ccRCC. Zelba et al.\textsuperscript{23} used flow cytometry analysis to reveal that PD-1 and LAG-3 were the most frequently upregulated inhibitory receptors within RCC tumor-infiltrating lymphocytes. Most recently, there was a report of poor survival in ccRCC with LAG-3 expression and LAG-3 DNA methylation.\textsuperscript{24}

In this tissue-based cohort study on surgically resected ccRCC, we found that LAG-3 expression is a prognostic indicator for poor CSS in ccRCC. Unlike previous studies reporting a simple survival analysis according to the LAG-3 expression status,\textsuperscript{22,24} our study analyzed the predictive and prognostic implication of LAG-3 in comparison with various clinicopathological features associated with aggressive tumor behavior, including pT stage, grade, lymphovascular invasion, tumor necrosis, and sarcomatoid features, in tissue samples from patients with ccRCC. In fact, LAG-3 immunopositivity on ICs in tumor tissues was associated with an advanced pT stage and higher Fuhrman nuclear grade.

The major strength of our study was the examination of the correlation between LAG-3 and PD-L1 expression and the synergistic effect on ccRCC prognosis when both immune checkpoint molecules were expressed simultaneously. The expression rate of PD-L1 on TCs was similar to that of previous studies, but the expression rate of PD-L1 on ICs was relatively lower than previous reports.\textsuperscript{15,26} Differences in patient cohorts, the types of antibodies used in immunohistochemistry experiments, and the selection of cutoffs can contribute to this discrepancy. The expression of PD-L1 on TCs or ICs was positively correlated with LAG-3 expression in our study. Our results demonstrated that PD-L1\(^+\)/LAG-3\(^+\) RCC patients had a poorer CSS than PD-L1\(^-\)/LAG-3\(^-\) RCC patients. Furthermore, in the multivariate analysis using a subgroup consisting of mRCC patients only, PD-L1 and LAG-3 coexpression was found to be a significant predictor of poor CSS. Because LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape,\textsuperscript{22} PD-L1\(^+\)/LAG-3\(^+\) RCC patients could have poorer CSS than PD-L1\(^-\), LAG-3\(^-\), or PD-L1\(^+\)/LAG-3\(^-\) RCC patients. A similar result was reported in a study comparing the relationship between LAG-3 and PD-L1 in non-small cell lung cancer.\textsuperscript{27}

Recent clinical trials have shown that high levels of PD-L1 expression are associated with a worse prognosis, but when treated with PD-1/PD-L1 inhibitors, patients with higher levels of PD-L1 expression tend to respond
better to therapy. However, since a significant number of patients do not respond to PD-1/PD-L1-targeting therapy regardless of their PD-1/PD-L1 expression status, alternative pathways need to be identified to overcome refractory disease or resistance to anti-PD-1/PD-L1 treatment. After blocking PD-1/PD-L1, TCs can still counteract the activity of immune checkpoints and activate additional inhibitory pathways by expressing other immune checkpoints and their ligand within the tumor immune microenvironment. Indeed, LAG-3 cell-surface expression was upregulated in vitro upon PD-1 blockade with tiragolumab, anti-TGIT antibody, with PD-L1 has shown promising outcomes in the first-line setting for in advanced NSCLC. Similar to LAG-3, TIGIT, and PD-1/PD-L1 blockade have additive activity. Therefore, it is expected that LAG-3 and TIGIT will serve as co-inhibitory anti-tumor target together with anti-PD-1/PD-L1 treatment in ongoing clinical trials regarding advanced solid tumors including RCC.

Our study had several limitations. First, although we identified the association of LAG-3 expression in ccRCC with known risk factors for survival, some clinicopathological factors were not statistically significant because of our study’s retrospective design and relatively small number sample size. Furthermore, the calculation and justification of the sample size were not done in this study. Therefore, additional prospective studies with a large patient cohort are necessary to confirm our results. Second, the TMA of the primary tumor tissue cannot completely reflect the immune markers analyzed in the tumor microenvironment.

Besides LAG-3, T cell immunoreceptor with Ig and ITIM (TIGIT) is the next wave of co-inhibitory receptor target and is being explored in various stages of clinical trials in advanced solid tumors. TIGIT blockade restores antitumor immune activity by augmenting T-cell and NK cell function, and suppressing Treg-mediated immune suppression. In recent phase II clinical trial, the combination of tiragolumab, anti-TGIT antibody, with PD-L1 has shown promising outcomes in the first-line setting for in advanced NSCLC. Similar to LAG-3, TIGIT, and PD-1/PD-L1 blockade have additive activity. Therefore, it is expected that LAG-3 and TIGIT will serve as co-inhibitory anti-tumor target together with anti-PD-1/PD-L1 treatment in ongoing clinical trials regarding advanced solid tumors including RCC.

### Table 4. Univariate and multivariate Cox proportional analysis of pathologic parameters and LAG-3, PD-L1 expressions in mRCC patients.

|                | Univariate | Multivariate | Adjusted for LAG-3 and PD-L1 combination status |
|----------------|------------|--------------|--------------------------------------------------|
|                | HR         | 95% CI       | p value                                          |
| Pathologic T stage |            |              |                                                  |
| pT1            | 1.01       | 0.88–1.15    | 0.875                                            |
| pT2            | 1.46       | 0.42–5.06    | 0.551                                            |
| pT3            | 2.51       | 0.91–6.96    | 0.077                                            |
| pT4            | 5.35       | 1.24–23.10   | 0.025                                            |
| Fuhrman’s nuclear grade |      |              |                                                  |
| GI−G2          | 1.04       | Reference    |                                                  |
| G3             | 0.28       | 0.09–0.90    | 0.033                                            |
| G4             | 0.99       | 0.43–2.27    | 0.982                                            |
| Lymphovascular invasion (negative vs Positive) | 3.17 | 1.44–6.99 | 0.004 | 2.84 | 1.14–7.08 | 0.025 | 2.64 | 0.80–8.72 | 0.111 |
| Sarcomatoid features (negative vs Positive) | 1.76 | 0.59–5.22 | 0.311 | - | - | - | - | - |
| Tumor necrosis (negative vs Positive) | 1.81 | 0.86–3.82 | 0.119 | - | - | - | - | - |
| LAG-3 (negative vs Positive) | 2.51 | 1.01–6.25 | 0.049 | 2.17 | 0.77–6.15 | 0.143 | - | - |
| PD-L1 (negative vs Positive) | 2.03 | 0.93–4.43 | 0.038 | 1.35 | 0.53–3.41 | 0.528 | - | - |
| LAG-3 and PD-L1 combination (both negative vs. Both positive) | 3.39 | 0.96–11.99 | 0.003 | - | - | - | 3.19 | 0.77–13.67 | 0.033 |

*Multivariate analysis (adjusted for LAG-3 or PD-L1 expression status) was performed using statistically significant variables (p<0.05) excluding LAG-3 and PD-L1 combination.
Additionally, although we showed LAG-3 and PD-L1 expression on ICs, we could not evaluate the IC type-specific expression of either checkpoint molecule. Third, the evaluation of immunohistochemical stain was performed by only one pathologist in this study. Each microscopic scoring result was examined at least three times to avoid intrapersonal bias. Finally, despite recent advances in ICIs in the treatment of mRCC, our study only includes a survival analysis of mRCC patients who were treated with targeted therapy. However, because previous studies show the poor prognostic role of PD-L1 expression in mRCC patients who were treated with targeted therapy, our results of the analysis of the prognostic role of LAG-3 in ccRCC and mRCC could be clinically relevant. 34,35 In the near future, the results of ongoing clinical trials using an anti-LAG-3 antibody, such as relatlimab, will be used to determine the prognostic role of LAG-3 for various solid tumors, including RCC. 11

Conclusion

We demonstrated that LAG-3 and PD-L1 expression in ccRCC is positively correlated with adverse clinicopathological features. Additionally, the coexpression of LAG-3 and PD-L1 predicts poor clinical outcomes in ccRCC. These findings provide a scientific rationale for LAG-3 blockade in combination with PD-1/PD-L1 blockade as a potential therapeutic approach for ccRCC. Data from ongoing clinical trials are required to validate these hypotheses.

Acknowledgements

The biospecimens used in this study were provided by the Inje Biobank of Inje University Busan Paik Hospital, a member of Korea Biobank Network. The preprint of this article was submitted to Research Square: https://doi.org/10.21203/rs.3.rs-1413598/v1

Authors’ contributions

Chan ho Lee, Soo Jin Jung, and Inhak Choi designed the study, performed statistical analysis and drafted the article. Youkyoung Jeon helped to download TCGA data and performed analysis. Won Ik Seo, Jae Il Chung, Dae Hoon Jeong, and Dae Sim Lee performed data collection and analysis. All authors have commented on previous versions of manuscript and approved the final manuscript.

Declaration of conficting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT; No. 2020R1F1A1071003).

Ethics approval

This study was approved by the Busan Paik Hospital Institutional Review Board (IRB No. 20–0121) and was in compliance with ethical guidelines according to the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from all subjects before the study.

ORCID iD

Chan Ho Lee  https://orcid.org/0000-0002-7750-6806

Supplemental Material

Supplemental material for this article is available online.

References

1. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A and Bray F. International variations and trends in renal cell carcinoma incidence and mortality. European Urology: 2015; 67: 519–530.
2. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. Journal of Clinical Oncology: 2005; 23: 832–841.
3. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology: 2009; 27: 5794–5799.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology: 2009; 27: 3584–3590.
5. Sternberg CN, Davis ID, Mardia J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology: 2010; 28: 1061–1068.
6. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med: 2015; 373: 1803–1813.
7. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England Journal of Medicine: 2018; 378: 1277–1290.
8. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). Journal for ImmunoTherapy of Cancer: 2019; 7: 354.
9. Zarour HM. Reversing T-cell Dysfunction and Exhaustion in Cancer. *Clinical Cancer Research* 2016; 22: 1856–1864.
10. Andrews LP, Marciscano AE, Drake CG and Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. *Immunological Reviews*. 2017; 276: 80–96.
11. Puhr HC and Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. *ESMO Open*. 2019; 4: e000482.
12. Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: An update to the integrated cancer data analysis platform. *Neoplasia*. 2022; 25: 18–27.
13. Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Research*. 2017; 77: e108–e110.
14. Burugu S, Gao D, Leung S, Chia SK and Nielsen TO. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. *Annals of Oncology*. 2017; 28: 2977–2984.
15. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *The New England Journal of Medicine*. 2019; 380: 1103–1115.
16. Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. *Journal of the National Comprehensive Cancer Network*. 2020; 18: 1160–1170.
17. Workman CJ, Rice DS, Dugger KJ, Kurschner C and Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). *European Journal of Immunology*. 2002; 32: 2255–2263.
18. Panda A, Rosenfeld JA, Singer EA, Bhanot G and Ganesan S. Genomic and immunologic correlates of LAG-3 expression in cancer. *OncolImmunology*. 2020; 9: 17566116–17566116.
19. Guo M, Yuan F, Qi F, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis. *Journal of Translational Medicine*. 2020; 18: 306.
20. Matsuzaki J, Gnajtic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107: 7875–7880.
21. Baitsh L, Baumgaertner P, Devèvre E, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. *Journal of Clinical Investigation*. 2011; 121: 2350–2360.
22. Giraldo NA, Becht E, Pagès F, et al. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. *Clinical Cancer Research*. 2015; 21: 3031–3040.
23. Zelba H, Bedek J, Hennenlotter J, et al. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. *Cancer Immunology Research*. 2019; 7: 1891–1899.
24. Klümper N, Rasler DJ, Bawden EG, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. *Journal for ImmunoTherapy of Cancer*. 2020; 8, e000552.
25. Tumeh PC, Harview CL, Yearle JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*. 2014; 515: 568–571.
26. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. *Cancer Research*. 2006; 66: 3381–3385.
27. He Y, Yu H, Rozeboom L, et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. *Journal of Thoracic Oncology*. 2017; 12: 814–823.
28. Satì N, Boyne DJ, Cheung WY, Cash SB and Arora P. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2021; 4: e2034201.
29. Toor SM, Saisidharan Nair V, Decock J and Elkord E. Immune checkpoints in the tumor microenvironment. *Seminars in Cancer Biology*. 2020; 65: 1–12.
30. Ascierto PA, Bono P, Blatia S, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. *Annals of Oncology*. 2017; 28: v611–v612.
31. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. *The New England Journal of Medicine*. 2022; 386: 24–34.
32. Ge Z, Peppelenbosch MP, Sprengers D and Kwekkeboom J. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. *Frontiers in Immunology*. 2021; 12: 699895.
33. Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. *Lancet Oncologist*. 2022; 23: 781–792.
34. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. *Clinical Cancer Research*. 2015; 21: 1071–1077.
35. Shin SJ, Jeon YK, Cho YM, et al. The Association Between AR-V7 and Prognosis of Patients With Metastatic Clear Cell Renal Cell Carcinoma. *Oncologist*. 2015; 20: 1253–1260.